(Q34427647)

2 August 2017

Going viral with cancer immunotherapy (English)

1 reference

2 August 2017

1 reference

4

John C Bell

1 reference

2 August 2017

3

David F Stojdl

1 reference

2 August 2017

1

Brian D Lichty

1 reference

2 August 2017

Caroline J Breitbach

2

1 reference

PubMed ID

24990523

2 August 2017

language of work or name

English

0 references

publication date

3 July 2014

1 reference

2 August 2017

Nature Reviews Cancer

1 reference

2 August 2017

14

1 reference

2 August 2017

8

1 reference

2 August 2017

559-567

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3770

2 August 2017

0 references

cites work

Monoclonal antibodies to phosphotyrosine

1 reference

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

Targeting the tumor mutanome for personalized vaccination therapy

31 March 2020

1 reference

31 March 2020

Oncolytic virotherapy

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

History of oncolytic viruses: genesis to genetic engineering

31 March 2020

1 reference

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

31 March 2020

1 reference

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

31 March 2020

1 reference

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

31 March 2020

1 reference

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

31 March 2020

1 reference

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

31 March 2020

1 reference

Targeting tumor vasculature with an oncolytic virus

31 March 2020

1 reference

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

31 March 2020

1 reference

Trial watch: Oncolytic viruses for cancer therapy

31 March 2020

1 reference

New viruses for cancer therapy: meeting clinical needs

31 March 2020

1 reference

Evolution of oncolytic viruses: novel strategies for cancer treatment

31 March 2020

1 reference

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

31 March 2020

1 reference

China approves world's first oncolytic virus therapy for cancer treatment

31 March 2020

1 reference

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

31 March 2020

1 reference

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

31 March 2020

1 reference

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

31 March 2020

1 reference

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

31 March 2020

1 reference

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

31 March 2020

1 reference

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

31 March 2020

1 reference

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy

31 March 2020

1 reference

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

31 March 2020

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

31 March 2020

1 reference

Adoptive-cell-transfer therapy for the treatment of patients with cancer

31 March 2020

1 reference

Gene-engineered T cells for cancer therapy

31 March 2020

1 reference

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus

31 March 2020

1 reference

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

31 March 2020

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

31 March 2020

1 reference

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells

31 March 2020

1 reference

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

31 March 2020

1 reference

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

31 March 2020

1 reference

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans

31 March 2020

1 reference

Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

31 March 2020

1 reference

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice

31 March 2020

1 reference

Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection

31 March 2020

1 reference

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

31 March 2020

1 reference

Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma

31 March 2020

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

31 March 2020

1 reference

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

31 March 2020

1 reference

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers

31 March 2020

1 reference

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

31 March 2020

1 reference

Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy

31 March 2020

1 reference

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

31 March 2020

1 reference

Smac mimetics and innate immune stimuli synergize to promote tumor death

31 March 2020

1 reference

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

31 March 2020

1 reference

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors

31 March 2020

1 reference

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells

31 March 2020

1 reference

IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner

31 March 2020

1 reference

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy

31 March 2020

1 reference

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

31 March 2020

1 reference

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

31 March 2020

1 reference

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

31 March 2020

1 reference

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

31 March 2020

1 reference

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer

31 March 2020

1 reference

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

31 March 2020

1 reference

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

31 March 2020

1 reference

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

31 March 2020

1 reference

Recombinant viral vectors: cancer vaccines

31 March 2020

1 reference

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

31 March 2020

1 reference

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

31 March 2020

1 reference

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

31 March 2020

1 reference

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

31 March 2020

1 reference

Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

31 March 2020

1 reference

Potentiating cancer immunotherapy using an oncolytic virus

31 March 2020

1 reference

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

31 March 2020

1 reference

Maraba virus as a potent oncolytic vaccine vector

31 March 2020

1 reference

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

31 March 2020

1 reference

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

31 March 2020

1 reference

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

31 March 2020

1 reference

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

31 March 2020

1 reference

Autophagy mediates the metabolic benefits of endurance training

31 March 2020

1 reference

Necroptosis: the release of damage-associated molecular patterns and its physiological relevance

31 March 2020

1 reference

Immunogenic cell death and DAMPs in cancer therapy

31 March 2020

1 reference

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

31 March 2020

1 reference

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

31 March 2020

1 reference

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model

31 March 2020

1 reference

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

31 March 2020

1 reference

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

31 March 2020

1 reference

Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors

31 March 2020

1 reference

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus

31 March 2020

1 reference

Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.

31 March 2020

1 reference

Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.

31 March 2020

1 reference

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

31 March 2020

1 reference

Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation

31 March 2020

1 reference

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity

31 March 2020

1 reference

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

31 March 2020

1 reference

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

31 March 2020

1 reference

Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy

31 March 2020

1 reference

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

31 March 2020

1 reference

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

31 March 2020

1 reference

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.

31 March 2020

1 reference

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.

31 March 2020

1 reference

Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms

31 March 2020

1 reference

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

31 March 2020

1 reference

Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma

31 March 2020

1 reference

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1

31 March 2020

1 reference

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

31 March 2020

1 reference

Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame

31 March 2020

1 reference

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

31 March 2020

1 reference

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy

31 March 2020

1 reference

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

31 March 2020

1 reference

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

31 March 2020

1 reference

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus

31 March 2020

1 reference

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL

31 March 2020

1 reference

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

31 March 2020

1 reference

Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice

31 March 2020

1 reference

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

31 March 2020

1 reference

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

31 March 2020

1 reference

Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand

31 March 2020

1 reference

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

31 March 2020

1 reference

Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus

31 March 2020

1 reference

A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes

31 March 2020

1 reference

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

31 March 2020

1 reference

12 December 2020

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

1 reference

12 December 2020

Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.

1 reference

12 December 2020

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

1 reference

12 December 2020

In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.

1 reference

12 December 2020

Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression

1 reference

12 December 2020

Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3770

1 reference

PubMed ID

24990523

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

24990523